An infection expert on Thursday said the contentious Dengvaxia vaccine will assist if “used correctly” in future dengue epidemics.
Scientific proof is overwhelming that it will be helpful for patients who have already had dengue or patients who have not effectively completed their 3 series.
After recording 146,062 instances of dengue, the government proclaimed a domestic dengue epidemic with 622 fatalities as of July 20. The figure is twice that of the 73,818 cases recorded last year during the same period.
Salvana, director of the National Institutes of Health’s Institute of Molecular Biology and Biotechnology, agreed with health authorities that the vaccine would have “minimal effect” on the present dengue epidemic, but it would have made a difference if the vaccine were used six months earlier.
The government doctor added that there’s “no reasonable scientific argument” for government not to lift its ban on Dengvaxia, citing the approval of the European Union (EU) and the United States Food and Drug Administration (FDA), which he said was one of the most stringent in the world.
Salvana said there’s no proof yet that the controversial vaccine is linked to deaths.
It doesn’t cause death in and of itself, but it can increase the risk to 5 out of 1,000, which is the same as that of somebody who has had dengue before but did not get the vaccine.Salvana added that those who examine the patients who allegedly died from the vaccine must be forensic pathologists and not forensic specialists.Reports of alleged deaths due to Dengvaxia have spawned a vaccination scare that led to a drop in immunization coverage in the country to 40 percent last year, from an average 70 percent in recent years.